Head-to-head evidence
adalimumab-adbm (Cyltezo) vs CT-P17
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
CT-P17
Developed by Celltrion
NCT03789292 · Phase 3 · completed
The trial was a large randomized, quadruple-blind comparison of CT-P17 and Humira, with 324 participants per initial treatment group. Its primary clinical endpoint, ACR20 response at Week 24, had identical reported counts in both groups, but the registry does not state whether the prespecified statistical comparison met its criterion, so the result is unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · CT-P17's landscape